Patent Application for Synthetic Promoters and Circuits in Cancer Cells
Summary
The USPTO has published a patent application (US20260085102A1) for nucleic acid molecules designed to specifically express sequences of interest in cancer cells. The application details synthetic promoters and circuits for use in cancer treatment.
What changed
This document is a published patent application from the USPTO detailing "Tissue Specific Synthetic Promoters and Circuits and Use Thereof." The application, US20260085102A1, filed on September 11, 2025, describes nucleic acid molecules configured for specific expression in cancer cells, comprising transcription factor binding regions, minimal promoters, and sequences of interest. It also covers related systems, compositions, and methods for treating cancer.
As a published patent application, this document does not impose immediate regulatory obligations or penalties on regulated entities. However, it signifies potential future developments in cancer therapeutics and gene expression technology. Companies in the pharmaceutical and biotechnology sectors, particularly those involved in oncology research and development, should monitor this and similar patent filings for insights into emerging technologies and potential intellectual property landscapes.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TISSUE SPECIFIC SYNTHETIC PROMOTERS AND CIRCUITS AND USE THEREOF
Application US20260085102A1 Kind: A1 Mar 26, 2026
Inventors
Lior NISSIM, Chaja KATZMAN, Tamar AMINOV, Masha ZAITSEV-CHAIKOVSKY, Nir SKALKA, Amit SHRAGA, Konstantin ROZENBERG, Chen SHIMONI, Inbar SHTEINBERG
Abstract
Nucleic acid molecules configured to specifically express a sequence of interest in a cancer cell, comprising: a transcription factor binding region comprising 3-10 repeats of a transcription factor binding site, a minimal promoter and the sequence of interest operatively linked to the transcription factor binding region and minimal promoter, wherein the transcription factor is selected from SOX9, GATA10, TCF7L1, LEF1, MYBL2 and MYB are provided. Nucleic acid molecule systems and compositions comprising the nucleic acid molecules are also provided as are methods of treating cancer.
CPC Classifications
C07K 14/5443 A61K 48/0058 A61P 35/00 C07K 14/55 C07K 14/70575 C12N 15/86 C12N 2740/15043 C12N 2830/60 C12N 2840/007
Filing Date
2025-09-11
Application No.
19325757
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.